Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer

Zhenfei Li, Andrew C. Bishop, Mohammad Alyamani, Jorge A. Garcia, Robert Dreicer, Dustin Bunch, Jiayan Liu, Sunil K. Upadhyay, Richard J. Auchus and Nima Sharifi ()
Additional contact information
Zhenfei Li: Lerner Research Institute, Cleveland Clinic
Andrew C. Bishop: Lerner Research Institute, Cleveland Clinic
Mohammad Alyamani: Lerner Research Institute, Cleveland Clinic
Jorge A. Garcia: Taussig Cancer Institute, Cleveland Clinic
Robert Dreicer: Taussig Cancer Institute, Cleveland Clinic
Dustin Bunch: Pathology and Laboratory Medicine Institute, Cleveland Clinic
Jiayan Liu: University of Michigan Medical School
Sunil K. Upadhyay: University of Michigan Medical School
Richard J. Auchus: University of Michigan Medical School
Nima Sharifi: Lerner Research Institute, Cleveland Clinic

Nature, 2015, vol. 523, issue 7560, 347-351

Abstract: The drug abiraterone is converted to Δ4-abiraterone (D4A) in mice and patients with prostate cancer, which has more potent anti-tumour activity and may lead to more effective therapies.

Date: 2015
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/nature14406 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:523:y:2015:i:7560:d:10.1038_nature14406

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature14406

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().